334 related articles for article (PubMed ID: 23252565)
1. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
Robak T
Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
Robak T
Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T; Robak P
Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
[TBL] [Abstract][Full Text] [Related]
4. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
5. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.
Stephens DM; Byrd JC
Hematol Oncol Clin North Am; 2013 Apr; 27(2):303-27. PubMed ID: 23561475
[TBL] [Abstract][Full Text] [Related]
6. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Robak T
Curr Cancer Drug Targets; 2008 Mar; 8(2):156-71. PubMed ID: 18336199
[TBL] [Abstract][Full Text] [Related]
7. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
8. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
[TBL] [Abstract][Full Text] [Related]
9. New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Laurenti L; De Padua L; D'Arena G; Vannata B; Innocenti I; Tarnani M; Deaglio S; Sica S; Efremov DG; Leone G
Mini Rev Med Chem; 2011 Jun; 11(6):508-18. PubMed ID: 21561405
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
13. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Robak T; Blonski JZ; Robak P
Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
15. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
16. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
17. Ofatumumab, a human anti-CD20 monoclonal antibody.
Osterborg A
Expert Opin Biol Ther; 2010 Mar; 10(3):439-49. PubMed ID: 20109133
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
Jain P; O'Brien S
Expert Opin Biol Ther; 2013 Feb; 13(2):169-82. PubMed ID: 23256681
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
